Jouvence Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Drug Discovery Tools; Genomics. Jouvence is dedicated to developing anti-aging therapies through genomics efforts. The company has licensed the LAG-1 gene, one of the first genes definitively linked to the longevity of an organism. Yeast strains in which the gene has been knocked out live 100% longer than average.